Adjunctive therapy in adult patients
VIMPAT DEMONSTRATED SIGNIFICANT CONTROL OF PARTIAL-ONSET SEIZURES
WITH OR WITHOUT SECONDARY GENERALIZATION.3-5*
Significantly more adult patients taking VIMPAT experienced a 50% or greater reduction in seizures from baseline compared with placebo.3-5
The efficacy of VIMPAT as adjunctive therapy in partial-onset seizures was established in three 12-week, randomized, multicenter, placebo-controlled, double-blind clinical trials.3-5
Pooled analysis of the results included 1294 adult patients with partial-onset seizures who were not adequately controlled with 1 to 3 concomitant antiepileptic drugs (AEDs), with or without additional vagus nerve stimulation (VNS).6
SELECT IMPORTANT SAFETY INFORMATION
Adjunctive therapy: In adult adjunctive placebo-controlled trials, the most frequently seen adverse reaction with VIMPAT was dizziness (31% vs 8% placebo). Other common adverse reactions occurring in ≥10 percent of VIMPAT-treated patients, and greater than placebo, were headache, nausea, and diplopia.
IN THE ADULT PLACEBO-CONTROLLED ADJUNCTIVE THERAPY CLINICAL TRIALS,
VIMPAT DEMONSTRATED EFFICACY WHEN ADDED TO A BROAD RANGE OF AEDs.6
Pooled baseline demographics and characteristics across 3 pivotal adult adjunctive therapy trials (N=1294)
- Age (mean): 38.6 years
- Female 51.1%, male 48.9%
- Patients averaged 23 years since diagnosis of epilepsy
- 45% of patients had tried 7 or more AEDs in his or her lifetime
- 84% of patients were on 2 or 3 concomitant AEDs when VIMPAT or placebo was added
- Average seizure frequency was 11.5 seizures every 28 days
- History of, or presently having: simple partial seizures, 32% (n=416); complex partial seizures, 84% (n=1087); partial seizures with secondary generalization, 42% (n=540)1‡
‡Some patients experienced more than 1 seizure type at baseline and, therefore, were represented in more than 1 group.
VIMPAT was added to 1 to 3 concomitant AEDs in placebo-controlled adjunctive therapy pivotal trials in adult patients.6
§Levetiracetam is a product manufactured by UCB.
Download Complementary Adjunctive Therapy Adult Pivotal Trial Publications
Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures.
Chung S, Sperling MR, Biton V, et al; on behalf of the SP754 Study Group. Lacosamide as adjunctive therapy for partial-onset seizures: A randomized controlled trial.
Halász P, Kälviäinen R, Mazurkiewicz-Bełdzińska M, et al. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial.